Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study unconfirmed

Story checked

Study establishes new perioperative standard in prostate cancer (opens in a new tab)

news-medical.net · 2026-10-27

Short answerEvidenceSource

Short answer

Source study unconfirmed

Study not confirmed.

The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.

15 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

No single source study could be confirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

View article claims
3

Search result

Source study unconfirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

Source paper

Source layer

The paper behind the story

The source record for this check.

The research anchor for the report.

  • Also referencedpresented as the new finding

    https://www.dana-farber.org/newsroom/news-releases/2026/perioperative-apalutamide-in-high-risk-localized-or-locally-advanced-prostate-cancer-substudy-supports-reduced-risk-of-metastasis-and-death

    Where the story links (opens in a new tab)
The literature search

15 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 11 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 4Not checkedAn international phase 3 clinical trial tested apalutamide plus hormone therapy before and after prostate cancer surgery in patients with high-risk localized and locally advanced prostate cancer.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 4Not checkedA substudy reportedly demonstrated a reduced risk of metastasis or death compared with standard of care.View evidenceHide evidence

As statedreduced risk of metastasis or death

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 4Not checkedThe substudy compared perioperative apalutamide plus ADT with radical prostatectomy alone and found superior efficacy for the combination.View evidenceHide evidence

As stated51 percent reduced risk of metastasis or death; 62 percent improvement in event-free survival

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 4Not checkedThe article says the combination reduced the risk of starting subsequent therapy and delayed later treatment, with side effects consistent with prior studies.View evidenceHide evidence

As stated71 percent reduced risk of starting a subsequent therapy; 33 months delayed subsequent therapy; 50 percent fewer patients started subsequent therapy by 3 years

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Benefits Seen With Apalutamide Plus ADT in Metastatic Castration-Sensitive Prostate Cancer

Default Digital Object Group · 2019 · Crossref

Source (opens in a new tab)
Candidate

Faculty Opinions recommendation of Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · 2018 · Crossref

Source (opens in a new tab)

Explore all search results